PCSK9抑制剂在无既往缺血事件的ASCVD患者中的疗效观察
意向性治疗分析显示,PCSK9i组5年复合终点事件率17.5%,低于对照组的25.4%,相对风险降低30.9%,绝对风险降低7.8%。
要点
- 无既往缺血事件的ASCVD患者使用PCSK9i单抗与5年缺血事件和死亡风险降低相关。
- PCSK9i组5年复合终点事件率17.5%,对照组25.4%,相对风险降低30.9%。
- 启动者LDL-C平均绝对降低63.1 mg/dL,百分比降低53.6%。
核心结论
- 在无既往缺血事件的ASCVD患者中,PCSK9i单抗治疗与较低的缺血事件和死亡风险相关。
研究设计与样本
- 观察性研究,使用Optum研究数据库,纳入2016年1月至2022年12月启动PCSK9i单抗的患者,并以1:2倾向评分匹配非启动者作为对照。
主要发现
- 意向性治疗分析下,PCSK9i组5年复合终点事件率为17.5%(95%CI 15.5%, 19.5%),对照组为25.4%(95%CI 23.6%, 27.1%)。
- 相对风险降低30.9%,绝对风险降低7.8%。
- 心肌梗死相对风险降低28.3%(P < .0001),缺血性卒中相对风险降低26.4%(P = .02),全因死亡相对风险降低28.5%(P < .0001)。
- 启动者平均基线LDL-C为117.8 mg/dL,随访时为54.7 mg/dL(在治疗分析),绝对降低63.1 mg/dL,百分比降低53.6%。
临床怎么用
- 对于无既往缺血事件的ASCVD患者,PCSK9i单抗治疗可能降低5年缺血事件和死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Low-density lipoprotein cholesterol (LDL-C)-lowering therapies are proven effective in atherosclerotic cardiovascular disease (ASCVD), but real-world evidence for proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) monoclonal antibodies (mAb) remains limited. This study evaluated their impact in patients with ASCVD without prior ischaemic events. METHODS: Patients initiating PCSK9i mAb from January 2016 to December 2022 were identified in the Optum Research Database. A 1:2 propensity score-matched comparator cohort of PCSK9i non-initiators was developed. The primary endpoint was a composite of non-fatal myocardial infarction, non-fatal ischaemic stroke, or all-cause mortality. Key outcomes from the parametric G-formula were 5-year event rates, relative risk reduction (RRR) and absolute risk reduction (ARR), with intention-to-treat (ITT) analysis. Additional outcomes for PCSK9i mAb initiators included absolute and percent LDL-C reduction from baseline. RESULTS: Overall, 19 670 patients met selection criteria (6545 PCSK9i mAb initiators; 13 125 non-initiators). Baseline characteristics were well-balanced. Under ITT, estimated 5-year event rates were 17.5% [95% confidence interval (CI) 15.5%, 19.5%] with PCSK9i mAb vs 25.4% (95% CI 23.6%, 27.1%) without PCSK9i, yielding a RRR of 30.9% and ARR of 7.8%. Individual endpoints showed RRRs of 28.3% for myocardial infarction (P < .0001), 26.4% for ischaemic stroke (P = .02), and 28.5% for all-cause mortality (P < .0001). Among initiators, mean baseline and follow-up LDL-C were 117.8 and 54.7 mg/dL (on-treatment analysis), respectively, representing an absolute reduction of 63.1 mg/dL and percent reduction of 53.6%. CONCLUSIONS: In ASCVD patients without prior events in clinical practice, PCSK9i mAb treatment was associated with lower ischaemic event and mortality rates.
引用
- Bhatt DL, Perrone Filardi P, Khan I, et al. PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study. Eur Heart J. 2026. PMID: 41989103. doi:10.1093/eurheartj/ehag176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。